GSK plc announced on April 28, 2026, that the FDA accepted bepirovirsen for priority review and granted it Breakthrough Therapy Designation for chronic hepatitis B, potentially benefiting over 250 million global patients. The FDA has set a Prescription Drug User Fee Act goal date of October 26, 2026.